Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progression-free survival as endpoint in metastatic RCC?

× No keyword cloud information.

11 in total

1. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Authors: Qi Xue; Janice A Nagy; Eleanor J Manseau; Thuy L Phung; Harold F Dvorak; Laura E Benjamin
Journal: Arterioscler Thromb Vasc Biol Date: 2009-05-14 Impact factor: 8.311

Review 2. Current treatment considerations in metastatic renal cell carcinoma.

Authors: Housam Haddad; Brian I Rini
Journal: Curr Treat Options Oncol Date: 2012-06

3. Metastatic Renal Cancer: What Role for Everolimus?

Authors: Franck A Belibi; Charles L Edelstein
Journal: Clin Med Rev Oncol Date: 2010-02-18

4. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.

Authors: Chris Coppin
Journal: Biologics Date: 2010-05-25

Review 5. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

Authors: Z Mihaly; Z Sztupinszki; P Surowiak; B Gyorffy
Journal: Curr Cancer Drug Targets Date: 2012-09 Impact factor: 3.428

6. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.

Authors: T E Delea; A Khuu; D Y C Heng; T Haas; D Soulières
Journal: Br J Cancer Date: 2012-08-30 Impact factor: 7.640

7. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points.

Authors: L Lee; L Wang; M Crump
Journal: Ann Oncol Date: 2011-01-25 Impact factor: 32.976

8. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.

Authors: Inga Peters; Natalia Dubrowinskaja; Mahmoud Abbas; Christoph Seidel; Michael Kogosov; Ralph Scherer; Kai Gebauer; Axel S Merseburger; Markus A Kuczyk; Viktor Grünwald; Jürgen Serth
Journal: PLoS One Date: 2014-03-14 Impact factor: 3.240

9. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors: Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal: Onco Targets Ther Date: 2012-10-23 Impact factor: 4.147

10. Targeted therapies for renal cell carcinoma: more gains from using them again.

Authors: H K Gan; B Seruga; J J Knox
Journal: Curr Oncol Date: 2009-05 Impact factor: 3.677